Norgine Ventures completes €5 million Financing with Q3 Medical Devices

London, England, June 21, 2016 – Q3 Medical Devices today announced that it has received financing of
up to €5million from Norgine Ventures. This investment recognises the growth prospects of Q3 Medical
Devices, an Irish based holding company with multiple operations in Germany focused on the development,
manufacturing and distribution of minimally invasive devices for the treatment of patients with cardiology,
peripheral vascular and non-vascular diseases. The funding will help Q3 Medical finance its development
pipeline and grow its commercial sales.

Norgine Ventures is an entity of the Norgine group.

Q3 Medical is an Irish medical device developer with c. 120 staff and two subsidiaries in Germany
(QualiMed and AMG), developing and commercialising stents and other implantable devices used primarily
in interventional cardiology. Q3 Medical is focused on opportunities that will accelerate the expansion of its
core manufacturing base as well as enhanced capabilities for innovative developments, distribution channel
expansion, and accelerated product offering for patients with cardiology, peripheral vascular and nonvascular
diseases.

Peter Stein, Norgine Ventures CEO, said: “Norgine Ventures’ investment in Q3 Medical is a good illustration of our commitment to grow valuable assets that can drive innovation and improve healthcare outcomes”. He added: “Q3’s expertise and technology can bring a number of best in class products to the field of cardiology thereby improving the healthcare systems, enabling provision of the right device, to the right patient.”

Eric Mangiardi, Q3 Medical Devices CEO, said : “This investment will allow for further acceleration of our commercial growth as well as our in-house development and manufacturing capabilities focused around our novel platforms for our Micro Invasive and Bioresorbable technologies’’. He further added: “The Norgine investment is another validation of Q3’s business model focused on better patient care through the utilization of its Micro Invasive technology that minimises the size of the openings needed for operations and its Bioresorbable products that reduce complication rates and eliminate costly removal procedures.”

Notes to Editors:

For further information please contact

Norgine Ventures

Julien Michaux, Norgine Ventures, +441895826600, jmichaux@norgine.com

Q3 Medical Devices

Eric K Mangiardi, Q3 Medical, +353867827296 (Ireland), emangiardi@gmail.com

Media Contacts:

Isabelle Jouin, Norgine Corporate Communications, T: +44 (0)1895 453643

Charlotte Andrews, Norgine Corporate Communications, T: +44 (0)1895 453607

Wayne Abraham, Q3 Medical, +44 7908 017599, Abraham@q3medical.com

About Norgine and Norgine Ventures

Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In
2015, Norgine’s total revenue was €320 million and the company employs over 1,000 people.

Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that
offer real value to healthcare professionals, payers and patients. Norgine’s approach and infrastructure is
integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.

Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in
Harefield, UK. Norgine owns an R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed,
Wales and one in Dreux, France.

For more information, please visit www.norgine.com

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative
healthcare companies through the provision of debt-like financing in Europe and the US.

For more information, please visit www.norgineventures.com

NORGINE and the sail logo are trademarks of the Norgine group of companies.

About Q3 Medical Devices

Q3 Medical Devices Limited is an Irish based holding company with multiple operations in Germany. The
holding and its companies are focused on the development, manufacturing, and distribution of minimally
invasive devices for the treatment of patients with cardiology, peripheral vascular and non-vascular
diseases.

Q3 Medical Devices Limited was formed by a global group of entrepreneurs, manufactures, distributors,
industry doctors, and investors focused on the development and acquisition of medical device businesses.

For further information, please visit http://www.q3medical.com

About QualiMed Innovative Medizinprodukte GmbH

QualiMed, a wholly owned subsidiary of Q3 Medical, was founded in 1997 in Winsen, Germany near
Hamburg, where it develops, manufactures and sells implantable medical devices in the Cardiology,
Peripheral Vascular, and Non Vascular areas. The innovations are focused in the areas of Biodegradable
Products, Drug Device Combination Technologies, Catheter and Mechanical implant areas. Originally
founded as an OEM, the company’s products are now sold in over 50 countries worldwide through its OEM,
Private Label, and Own Brand Networks. The company and its development partners have obtained CE
and FDA approvals for more than 70 different products including 3 different drug eluting stents.

For further information, please visit http://www.qualimed.de